Cybin has announced a public offering for gross proceeds of US$8,250,000. The post Raising Capital: Cybin Announces Public Offering appeared first on ...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed The post News...
Psychedelics made their official debut in the Western world over half a century ago. However, there are still a lot of unknowns. The large gap in...
Cybin announces Phase 2 cohort 5 dosing completion of CYB003 in Major Depressive Disorder The post Cybin Announces Phase 2 Dosing Completion of CYB003...
Kernel, a leader in non-invasive neuroimaging, announces the publication of their study “Measuring acute effects of subanesthetic ketamine on cerebrovascular...
The first half of 2023 has come to an end, and so far, this year has been just as action-packed as 2022. The first two quarters...
Cybin Inc. (NEO:CYBN / NYSE American:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
As the medical community begins to set the stage for standardizing psychedelic treatments, Cybin Inc. (NEO:CYBN) (NYSE:CYBN) has decided to begin the...
On 6th July, PSYCH Symposium returns to London to explore emerging research, technologies and opportunities which have the potential to reshape the landscape...
Cybin Inc. (NEO:CYBN / NYSE American:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...